Abatacept Significantly Reduces Subclinical Inflammation During Treatment (6 Months), This Persists After Discontinuation (12 Months), Resulting in a Delay in the Clinical Development of RA in Patients at Risk of RA (The ARIAA Study)

Juergen Rech; Arnd Kleyer; Mikkel Østergaard; Melanie Hagen; Larissa Valor Mendez; Koray Taşçilar; Gerhard Kroenke; Verena Schönau; David Simon; Stefan Kleinert; Xenofon Baraliakos; Jürgen Braun; Axel Hueber; Martin Fleck; Andrea Rubbert-Roth; Frank Behrens; Martin Feuchtenberger; M Zaenker; Reinhard Voll; Cornelia Glaser; Maria Filkova; Eugen  Feist; Gerd Burmester; Kirsten Karberg; Johannes Strunk; Juan D. Cañete; Ladislav Šenolt; Esperanza Naredo; Georg Schett

Abatacept Significantly Reduces Subclinical Inflammation During Treatment (6 Months), This Persists After Discontinuation (12 Months), Resulting in a Delay in the Clinical Development of RA in Patients at Risk of RA (The ARIAA Study)

Juergen Rech, Arnd Kleyer, Mikkel Østergaard, Melanie Hagen, Larissa Valor Mendez, Koray Taşçilar, Gerhard Kroenke, Verena Schönau, David Simon, Stefan Kleinert, Xenofon Baraliakos, Jürgen Braun, Axel Hueber, Martin Fleck, Andrea Rubbert-Roth, Frank Behrens, Martin Feuchtenberger, M Zaenker, Reinhard Voll, Cornelia GlaserMaria Filkova, Eugen Feist, Gerd Burmester, Kirsten Karberg, Johannes Strunk, Juan D. Cañete, Ladislav Šenolt, Esperanza Naredo, Georg Schett

Department for Rheumatology and Spine Diseases

Abstract

Background/Purpose:
Development of the clinical phase of rheumatoid arthritis (RA) is preceded by an autoimmune phase, characterized by the presence of anti-citrullinated protein antibodies (ACPA), that gradually translates into clinical disease. Individuals with ACPA, but no clinical arthritis, that show signs of subclinical joint inflammation in the imaging are at particularly high risk to develop RA within a short time. We have previously shown that a 6-months treatment with abatacept not only inhibits the onset of RA but also reduces MRI signs of inflammation in such ACPA-positive high-risk individuals. However, it is currently unknown whether such time-limited intervention leads to sustained suppression of inflammation in the joints.

Original language	English
Publication date	2022
Publication status	Published - 2022
Event	The Thirteenth International Congress on Spondyloarthritides - Ghent, Belgium Duration: 7 Sept 2022 → 9 Sept 2022

Conference

Conference	The Thirteenth International Congress on Spondyloarthritides
Country/Territory	Belgium
City	Ghent
Period	07/09/2022 → 09/09/2022

Fingerprint

Dive into the research topics of 'Abatacept Significantly Reduces Subclinical Inflammation During Treatment (6 Months), This Persists After Discontinuation (12 Months), Resulting in a Delay in the Clinical Development of RA in Patients at Risk of RA (The ARIAA Study)'. Together they form a unique fingerprint.

Cite this

Rech, J., Kleyer, A., Østergaard, M., Hagen, M., Mendez, L. V., Taşçilar, K., Kroenke, G., Schönau, V., Simon, D., Kleinert, S., Baraliakos, X., Braun, J., Hueber, A., Fleck, M., Rubbert-Roth, A., Behrens, F., Feuchtenberger, M., Zaenker, M., Voll, R., ... Schett, G. (2022). Abatacept Significantly Reduces Subclinical Inflammation During Treatment (6 Months), This Persists After Discontinuation (12 Months), Resulting in a Delay in the Clinical Development of RA in Patients at Risk of RA (The ARIAA Study). Arthritis & Reumatology Vol. 74, number S9, p. 1067. Abstract from The Thirteenth International Congress on Spondyloarthritides, Ghent, Belgium.

Abatacept Significantly Reduces Subclinical Inflammation During Treatment (6 Months), This Persists After Discontinuation (12 Months), Resulting in a Delay in the Clinical Development of RA in Patients at Risk of RA (The ARIAA Study). / Rech, Juergen; Kleyer, Arnd; Østergaard, Mikkel et al.
2022. Arthritis & Reumatology Vol. 74, number S9, p. 1067 Abstract from The Thirteenth International Congress on Spondyloarthritides, Ghent, Belgium.

Research output: Contribution to conference › Conference abstract for conference › Research › peer-review

Rech, J, Kleyer, A, Østergaard, M, Hagen, M, Mendez, LV, Taşçilar, K, Kroenke, G, Schönau, V, Simon, D, Kleinert, S, Baraliakos, X, Braun, J, Hueber, A, Fleck, M, Rubbert-Roth, A, Behrens, F, Feuchtenberger, M, Zaenker, M, Voll, R, Glaser, C, Filkova, M, Feist, E, Burmester, G, Karberg, K, Strunk, J, Cañete, JD, Šenolt, L, Naredo, E & Schett, G 2022, 'Abatacept Significantly Reduces Subclinical Inflammation During Treatment (6 Months), This Persists After Discontinuation (12 Months), Resulting in a Delay in the Clinical Development of RA in Patients at Risk of RA (The ARIAA Study)', The Thirteenth International Congress on Spondyloarthritides, Ghent, Belgium, 07/09/2022 - 09/09/2022 pp. Arthritis & Reumatology Vol. 74, number S9, p. 1067.

Rech J, Kleyer A, Østergaard M, Hagen M, Mendez LV, Taşçilar K et al.. Abatacept Significantly Reduces Subclinical Inflammation During Treatment (6 Months), This Persists After Discontinuation (12 Months), Resulting in a Delay in the Clinical Development of RA in Patients at Risk of RA (The ARIAA Study). 2022. Abstract from The Thirteenth International Congress on Spondyloarthritides, Ghent, Belgium.

Rech, Juergen ; Kleyer, Arnd ; Østergaard, Mikkel et al. / Abatacept Significantly Reduces Subclinical Inflammation During Treatment (6 Months), This Persists After Discontinuation (12 Months), Resulting in a Delay in the Clinical Development of RA in Patients at Risk of RA (The ARIAA Study). Abstract from The Thirteenth International Congress on Spondyloarthritides, Ghent, Belgium.

@conference{ea4c0bfba4fa4316b5ca17d4b2bc5fb0,

title = "Abatacept Significantly Reduces Subclinical Inflammation During Treatment (6 Months), This Persists After Discontinuation (12 Months), Resulting in a Delay in the Clinical Development of RA in Patients at Risk of RA (The ARIAA Study)",

abstract = "Background/Purpose: Development of the clinical phase of rheumatoid arthritis (RA) is preceded by an autoimmune phase, characterized by the presence of anti-citrullinated protein antibodies (ACPA), that gradually translates into clinical disease. Individuals with ACPA, but no clinical arthritis, that show signs of subclinical joint inflammation in the imaging are at particularly high risk to develop RA within a short time. We have previously shown that a 6-months treatment with abatacept not only inhibits the onset of RA but also reduces MRI signs of inflammation in such ACPA-positive high-risk individuals. However, it is currently unknown whether such time-limited intervention leads to sustained suppression of inflammation in the joints.",

author = "Juergen Rech and Arnd Kleyer and Mikkel {\O}stergaard and Melanie Hagen and Mendez, {Larissa Valor} and Koray Ta{\c s}{\c c}ilar and Gerhard Kroenke and Verena Sch{\"o}nau and David Simon and Stefan Kleinert and Xenofon Baraliakos and J{\"u}rgen Braun and Axel Hueber and Martin Fleck and Andrea Rubbert-Roth and Frank Behrens and Martin Feuchtenberger and M Zaenker and Reinhard Voll and Cornelia Glaser and Maria Filkova and Eugen Feist and Gerd Burmester and Kirsten Karberg and Johannes Strunk and Ca{\~n}ete, {Juan D.} and Ladislav {\v S}enolt and Esperanza Naredo and Georg Schett",

note = "COPECARE; The Thirteenth International Congress on Spondyloarthritides ; Conference date: 07-09-2022 Through 09-09-2022",

year = "2022",

language = "English",

pages = "Arthritis & Reumatology Vol. 74, number S9, p. 1067",

}

TY - ABST

T1 - Abatacept Significantly Reduces Subclinical Inflammation During Treatment (6 Months), This Persists After Discontinuation (12 Months), Resulting in a Delay in the Clinical Development of RA in Patients at Risk of RA (The ARIAA Study)

AU - Rech, Juergen

AU - Kleyer, Arnd

AU - Østergaard, Mikkel

AU - Hagen, Melanie

AU - Mendez, Larissa Valor

AU - Taşçilar, Koray

AU - Kroenke, Gerhard

AU - Schönau, Verena

AU - Simon, David

AU - Kleinert, Stefan

AU - Baraliakos, Xenofon

AU - Braun, Jürgen

AU - Hueber, Axel

AU - Fleck, Martin

AU - Rubbert-Roth, Andrea

AU - Behrens, Frank

AU - Feuchtenberger, Martin

AU - Zaenker, M

AU - Voll, Reinhard

AU - Glaser, Cornelia

AU - Filkova, Maria

AU - Feist, Eugen

AU - Burmester, Gerd

AU - Karberg, Kirsten

AU - Strunk, Johannes

AU - Cañete, Juan D.

AU - Šenolt, Ladislav

AU - Naredo, Esperanza

AU - Schett, Georg

N1 - COPECARE

PY - 2022

Y1 - 2022

N2 - Background/Purpose: Development of the clinical phase of rheumatoid arthritis (RA) is preceded by an autoimmune phase, characterized by the presence of anti-citrullinated protein antibodies (ACPA), that gradually translates into clinical disease. Individuals with ACPA, but no clinical arthritis, that show signs of subclinical joint inflammation in the imaging are at particularly high risk to develop RA within a short time. We have previously shown that a 6-months treatment with abatacept not only inhibits the onset of RA but also reduces MRI signs of inflammation in such ACPA-positive high-risk individuals. However, it is currently unknown whether such time-limited intervention leads to sustained suppression of inflammation in the joints.

AB - Background/Purpose: Development of the clinical phase of rheumatoid arthritis (RA) is preceded by an autoimmune phase, characterized by the presence of anti-citrullinated protein antibodies (ACPA), that gradually translates into clinical disease. Individuals with ACPA, but no clinical arthritis, that show signs of subclinical joint inflammation in the imaging are at particularly high risk to develop RA within a short time. We have previously shown that a 6-months treatment with abatacept not only inhibits the onset of RA but also reduces MRI signs of inflammation in such ACPA-positive high-risk individuals. However, it is currently unknown whether such time-limited intervention leads to sustained suppression of inflammation in the joints.

M3 - Conference abstract for conference

SP - Arthritis & Reumatology Vol. 74, number S9, p. 1067

T2 - The Thirteenth International Congress on Spondyloarthritides

Y2 - 7 September 2022 through 9 September 2022

ER -